|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5-6
|
|
pubmed:dateCreated |
2008-2-11
|
|
pubmed:abstractText |
The aim of the present study was to evaluate the 6-month survival rate of patients with inoperable or metastatic pancreatic cancer treated with irinotecan and gemcitabine plus 5-fluorouracil. Secondary efficacy end points included response rate, time to progression (TTP), overall survival (OS) and toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0232
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2008 S. Karger AG, Basel
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
279-84
|
|
pubmed:meshHeading |
pubmed-meshheading:18187949-Adult,
pubmed-meshheading:18187949-Aged,
pubmed-meshheading:18187949-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18187949-Camptothecin,
pubmed-meshheading:18187949-Deoxycytidine,
pubmed-meshheading:18187949-Disease Progression,
pubmed-meshheading:18187949-Female,
pubmed-meshheading:18187949-Fluorouracil,
pubmed-meshheading:18187949-Humans,
pubmed-meshheading:18187949-Male,
pubmed-meshheading:18187949-Middle Aged,
pubmed-meshheading:18187949-Pancreatic Neoplasms,
pubmed-meshheading:18187949-Survival Analysis
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
|
|
pubmed:affiliation |
Department of Internal Medicine I, University of Regensburg, Regensburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
